Datamonitor launches
Cancer Review
The Cancer Review brings
you the latest news, analysis and research in the cancer industry. It
covers all the major current business issues and events, including
R&D, licensing deals, alliances and joint ventures, and regulatory
decisions.
Scope
-
Strategic insight
into the future shape of cancer companies and markets
-
The most significant
cancer industry news compiled into one monthly update
-
Expert analysis into
the implications of the month's important cancer industry events
-
Insight into the
future shape of the market for players at all levels
-
All the month's major
cancer stories in headline and summary form
Report Highlights
Out of the dozens of
topics covered in this month's review, the most important include:
* Japan became the first
country to approve AstraZeneca's Iressa for the treatment of inoperable or
recurrent non-small cell lung cancer. Iressa is the first in a new class
of anti-cancer drugs, known as EGF receptor inhibitors.
* Five non-profitable UK
biotech companies may be considering a merger, creating a new cancer
player capable of competing against the majors. But a more gradual
consolidation effort might suit the biotechs better
Reasons to Purchase
Not only keeps you
updated about industry events - it also gives you opinion and insight
Draws upon Datamonitor
analysts' extensive experience to bring you our perspective on the impact
of the latest events
Provides you with your
own news archive to track company and industry progress, giving you an
extensive reference to relevant events and issues
View
pdf brochure
Click
here to purchase online
